All Updates

All Updates

icon
Filter
Funding
Prolific Machines raises USD 55 million in Series B funding to begin commercialization efforts
Cell-cultured Meat
Jun 6, 2024
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Cell-cultured Meat

Cell-cultured Meat

Jun 6, 2024

Prolific Machines raises USD 55 million in Series B funding to begin commercialization efforts

Funding

  • Prolific Machines, a biotechnology company specializing in photo molecular biology, has raised USD 54.6 million in series B funding led by The Ki Tua Fund. Breakthrough Energy Ventures, Mayfield, SOSV, Shorewind Capital, Darco Capital, Conti Ventures, and In-Q-Tel (IQT) participated.

  • Prolific Machines will use the funding for commercialization and customer acquisition, marking the company’s transition from proving the efficacy of its process to actively delivering it to people. 

  • Prolific Machines enable the transition from expensive and hard-to-control molecules to a more efficient and sustainable method—light. Through its bioreactors, it offers customers efficient biomanufacturing of high-value bioproducts, including nutritional proteins, antibodies for disease treatment, and cultivated meat.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.